BRUCE D. HAMMOCK
PhD – Chairman of Scientific Advisory Board and Member of the Board of Directors
Dr. Hammock is a Distinguished Professor at the University of California-Davis Comprehensive Cancer Center. He is a member of the National Academy of Sciences and the National Academy of Inventors. One of the most important aspects of Dr. Hammock’s scientific contributions is his discovery of the soluble epoxide hydrolase early in his career. Many of his over 1200 publications and patents are on the P450 branch of the arachidonic acid cascade and the role of soluble epoxide hydrolase in fatty acid metabolism. He continues as the founding Director of the multi-million dollar NIEHS-UCD Superfund Research Program now renewed through its 35th year. He was Principal Investigator of the NIH Biotechnology Graduate Training Program at the University of California Davis for over 15 years. Dr. Hammock has been the director of an analytical laboratory supporting a variety of NIH funded programs for 20 years. He is a past NIH Career and Merit Awardee; a Burroughs Wellcome Scholar; and a von Humboldt, Marcus and Fulbright Fellow. He recently was selected for the Brodie Award in Xenobiotic Metabolism, the Lands Lecture in Biochemical Nutrition, and as the first McGiff Memorial Awardee in Lipid Biochemistry. He founded several companies, has helped raise over $50 million in private capital and currently is CEO of EicOsis developing an orally active non-addictive drug for inflammatory and neuropathic pain in man and companion animals. EicOsis is supported by several SBIR grants and a NIH NINDS Blueprint Development Grant.
Dipak Panigrahy
Dipak Panigrahy, MD – Eicosanoid pathophysiology in cancer biology
Dr. Panigrahy is an Assistant Professor of Pathology, Center for Vascular Biology Research, at the Beth Israel Deaconess Medical Center in Boston, MA. Dr. Panigrahy previously led cancer, inflammation, and angiogenesis animal tumor dormancy modeling in the Folkman laboratory where he developed extensive expertise in cancer biology and tumor models. His recognition in the field includes funding from the National Cancer Institute to study the involvement of soluble epoxide hydrolase (sEH) metabolism of EETs in cancer and metastasis. The novelty of Dr. Panigrahy’s work is demonstrated by the 50+ awards recognizing his group’s work on lipid autacoids in cancer. His laboratory has created unique chemotherapy, surgery, and carcinogen cell death (“debris”)-stimulated cancer models designed to evaluate novel pro-resolution (“debris clearing”) lipid mediators. Dr. Panigrahy has chaired over ten symposia and given over 45 invited lectures on lipid autacoids in cancer at national and international meetings over the past five years.
GET IN TOUCH
Office
12636 High Bluff Drive, Suite 400, San Diego, CA 92130, USA